Obstetric and perinatal outcomes of maternal COVID-19 disease

Case-control study

  • Cecilia Santos Asociación Española Primera de Socorros Mutuos, Departamento de Ginecología y Obstetricia
  • Danilo Magallanes Asociación Española Primera de Socorros Mutuos, Departamento Clínico de Medicina
  • Melina Rubiños Asociación Española Primera de Socorros Mutuos, Departamento Clínico de Medicina
  • Álvaro Danza Universidad de la República, Facultad de Medicina, Hospital Pasteur, Clínica Médica 2
DOI: https://doi.org/10.29193/RMU.39.3.4
Keywords: COVID-19, PREGNANCY, INFECTIOUS COMPLICATIONS OF PREGNANCY, NEWBORN

Abstract

Introduction: Viral infections during pregnancy can lead to maternal and fetal complications. It is important to describe the maternal and fetal implications of COVID-19 disease.
Objetives: To describe and analyze the characteristics of patients who experienced SARS-CoV-2 infection during gestation, and maternal and fetal outcomes.
Method: A case-control study was conducted. All pregnant patients who presented SARS-CoV-2 infection and were hospitalized in a private healthcare institution (cases) during the period 1/03/2021 – 31/07/2021 were included in the study. Controls were selected from pregnant patients who were admitted during the same time but tested negative for SARS-CoV-2. Two controls were included for each case. The maternal variables considered were preterm labor, gestational diabetes, preeclampsia, (severe or non-severe) preeclampsia, fetal death, fetal growth restriction, placental abruption. The neonatal variables considered were vital status, newborn weight, one-minute and five-minute Apgar scores, need for admission to a specialized neonatal care unit, and length of stay in days. COVID-19 tests for the newborn and their condition at discharge were recorded.
Results: Maternal demographic characteristics were comparable in both groups. Twenty-one (55%) obstetric complications were observed in the case group, and 117 (44.7%) in the control group; OR= 4.2 (95% CI:   1.9-9.7).  Twenty-one (30.8%) neonatal complications were observed in the case group, and 3 (3.8%) in the control group; OR= 11.2 (95% CI: 2.9-42.9). The case group was associated with a lower likelihood of being vaccinated; OR = 0.3 (95% CI:  0.13-0.75).
Conclusions: We report an increased risk of adverse maternal and neonatal outcomes associated with SARS-CoV-2 virus infection. Vaccination proves to be a valuable tool against this viral infection.

References

1) World Health Organization. Coronavirus disease (COVID-19). Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Consulta: 15 noviembre 2022].
2) Khan M, Adil S, Alkhathlan H, Tahir M, Saif S, Khan M, et al. COVID-19: a global challenge with old history, epidemiology and progress so far. Molecules 2020; 26(1):39. doi: 10.3390/molecules26010039.
3) Bedoya Sommerkamp M, Medina Ranilla J, Chau Rodríguez V, Soldevilla R, Vera Albújar Á, García P. Variantes del SARS-CoV-2: epidemiología, fisiopato-logía y la importancia de las vacunas. Rev Perú Med Exp Salud Pública 2021; 38(3):442-51. doi: 10.17843/rpmesp.2021.383.8734.
4) Adhikari E, MacDonald L, SoRelle J, Morse J, Pruszynski J, Spong CY. COVID-19 cases and disease severity in pregnancy and neonatal positivity associated with Delta (B.1.617.2) and Omicron (B.1.1.529) variant predomi-nance. JAMA 2022; 327(15):1500-2. doi: 10.1001/jama.2022.4356.
5) Mupanomunda M, Fakih M, Miller C, Ottenbacher A, Winegar A, Roberts P, et al. Comparison of severe maternal morbidities associated with delivery dur-ing periods of circulation of specific SARS-CoV-2 variants. JAMA Netw Open 2022; 5(8):e2226436. doi: 10.1001/jamanetworkopen.2022.26436.
6) Briozzo L, Tomasso G, Viroga S, Nozar F, Bianchi A. Impact of mitigation measures against the COVID 19 pandemic on the perinatal results of the refer-ence maternity hospital in Uruguay. J Matern Fetal Neonatal Med 2022; 35(25):5060-2. doi: 10.1080/14767058.2021.1874911.
7) Sobrero H, Balerio A, Clavijo F, Alaniz A, Lemes M, Ramírez P, et al. Des-cripción de resultados perinatales en madres COVID positivas asistidas en un medio público y uno privado de Montevideo en el período marzo 2020-junio 2021. Rev Méd Urug 2022; 38(4):e38405. doi: 10.29193/RMU.38.4.4.
8) Tan E, Tan E. Alterations in physiology and anatomy during pregnancy. Best Pract Res Clin Obstet Gynaecol 2013; 27(6):791-802. doi: 10.1016/j.bpobgyn.2013.08.001.
9) Hegewald M, Crapo R. Respiratory physiology in pregnancy. Clin Chest Med 2011; 32(1):1-13. doi: 10.1016/j.ccm.2010.11.001.
10) Kumar M, Saadaoui M, Al Khodor S. Infections and pregnancy: effects on maternal and child health. Front Cell Infect Microbiol 2022; 12:873253. doi: 10.3389/fcimb.2022.873253.
11) Dashraath P, Wong J, Lim M, Lim L, Li S, Biswas A, et al. Coronavirus dis-ease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020; 222(6):521-31. doi: 10.1016/j.ajog.2020.03.021.
12) Moore K, Suthar M. Comprehensive analysis of COVID-19 during pregnan-cy. Biochem Biophys Res Commun 2021; 538:180-6. doi: 10.1016/j.bbrc.2020.12.064.
13) Ortiz E, Herrera E, De La Torre A. Coronavirus (COVID 19) Infection in Pregnancy. Colomb Med (Cali) 2020; 51(2):e4271. doi: 10.25100/cm.v51i2.4271.
14) Silasi M, Cardenas I, Kwon J, Racicot K, Aldo P, Mor G. Viral infections dur-ing pregnancy. Am J Reprod Immunol 2015; 73(3):199-213. doi: 10.1111/aji.12355.
15) Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7):934-43. doi: 10.1001/jamainternmed.2020.0994.
16) Wang C, Liu Y, Wu C, Wang C, Wang C, Long C. Impact of COVID-19 on pregnancy. Int J Med Sci 2021; 18(3):763-7. doi: 10.7150/ijms.49923.
17) Röbl-Mathieu M, Kunstein A, Liese J, Mertens T, Wojcinski M. Vaccination in Pregnancy. Dtsch Arztebl Int 2021; 118(15):262-8. doi: 10.3238/arztebl.m2021.0020.
18) Vojtek I, Dieussaert I, Doherty T, Franck V, Hanssens L, Miller J, et al. Ma-ternal immunization: where are we now and how to move forward? Ann Med 2018; 50(3):193-208. doi: 10.1080/07853890.2017.1421320.
19) Blakeway H, Prasad S, Kalafat E, Heath P, Ladhani S, Le Doare K, et al. COVID-19 vaccination during pregnancy: coverage and safety. Am J Obstet Gynecol 2022; 226(2):236.e1-236.e14. doi: 10.1016/j.ajog.2021.08.007.
20) Decreto 158/019. Investigación en seres humanos. Montevideo, 12 de ju-nio de 2019. Montevideo: IMPO, 2019. Disponible en: https://www.impo.com.uy/bases/decretos-originales/158-2019. [Consulta: 15 noviembre 2022].
21) Organización Panamericana de la Salud. Consejo de Organizaciones In-ternacionales de las Ciencias Médicas. Pautas éticas internacionales para la investigación relacionada con la salud con seres humanos. 4 ed. Ginebra: CIOMS, 2016. Disponible en: https://cioms.ch/wp-content/uploads/2017/12/CIOMS-EthicalGuideline_SP_INTERIOR-FINAL.pdf. [Consulta: 19 marzo 2022].
22) Chen H, Chauhan S. Hypertension among women of reproductive age: impact of 2017 American College of Cardiology/American Heart Association high blood pressure guideline. Int J Cardiol Hypertens 2019; 1:100007. doi: 10.1016/j.ijchy.2019.100007.
23) Wei S, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 2021; 193(16):E540-8. doi: 10.1503/cmaj.202604.
24) Yao X, Zhu L, Yin J, Wen J. Impacts of COVID-19 pandemic on preterm birth: a systematic review and meta-analysis. Public Health 2022; 213:127-34. doi: 10.1016/j.puhe.2022.10.015.
25) Schwartz D. An analysis of 38 pregnant women with COVID-19, their new-born infants, and maternal-fetal transmission of SARS-CoV-2: maternal coro-navirus infections and pregnancy outcomes. Arch Pathol Lab Med 2020; 144(7):799-805. doi: 10.5858/arpa.2020-0901-SA.
26) Jamieson D, Rasmussen S. An update on COVID-19 and pregnancy. Am J Obstet Gynecol 2022; 226(2):177-86. doi: 10.1016/j.ajog.2021.08.054.
27) Hui L, Marzan M, Rolnik D, Potenza S, Pritchard N, Said J, et al. Reduc-tions in stillbirths and preterm birth in COVID-19-vaccinated women: a multi-center cohort study of vaccination uptake and perinatal outcomes. Am J Obstet Gynecol 2023; 228(5):585.e1-585.e16. doi: 10.1016/j.ajog.2022.10.040.
28) Aguirre R, Antón J, Triunfo P. Análisis de las cesáreas en Uruguay por tipo de centro hospitalario. Gac Sanit 2019; 33(4):333-40. doi: 10.1016/j.gaceta.2018.01.004.
29) Di Toro F, Gjoka M, Di Lorenzo G, De Santo D, De Seta F, Maso G, et al. Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis. Clin Microbiol Infect 2021; 27(1):36-46. doi: 10.1016/j.cmi.2020.10.007.
30) Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Out-come of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020; 2(2):100107. doi: 10.1016/j.ajogmf.2020.100107.
Published
2023-09-04
How to Cite
1.
Santos C, Magallanes D, Rubiños M, Danza Álvaro. Obstetric and perinatal outcomes of maternal COVID-19 disease. Rev. Méd. Urug. [Internet]. 2023Sep.4 [cited 2024May17];39(3):e204. Available from: http://www2.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/1039
Issue
Vol 39 No 3 (2023): Revista Médica del Uruguay
Section
Original Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.